Overview

Suvorexant in Insomnia Co-morbid With Fibromyalgia

Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Suvorexant